Charles M. Walworth, MD, of Labcorp discusses a new hepatitis D reflex pathway, internal data showing 8.3% of HBsAg-positive patients screened for HDV, and lessons from hepatitis C reflex testing.
News|Articles|November 24, 2023
Infectious Disease News This Week
Author(s)John Parkinson
In this week's news, we covered the HCV elimination program, recent food recalls, live biotherapeutic products for recurrent C diff, and the availability of a monoclonal antibody for RSV prevention in infants.
Advertisement
Advertisement
Related to this article
The FDA approved bepirovirsen (Hibsago; GSK) with nucleos(t)ide analogue therapy for chronic hepatitis B, based on B-Well 1 and 2 functional cure rates of 19% vs 0% with placebo.
The antifungal pipeline currently contains 22 agents in the clinical program and many more in the pre-clinical program. Novel products in the clinical program are especially encouraging.
Dr. Reddy’s generic twice-yearly lenacapavir received FDA tentative approval for HIV PrEP. It is expected to cost $40 a year in 120 low- and middle-income countries (LMICs), with first supplies due by the end of 2026.
David Altarac, MD, discusses 2025 SENTRY data, ESBL considerations in empiric therapy, and where ceftobiprole fits alongside ceftaroline in S aureus bacteremia.
A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.
Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
2
Fungal-WHAT? Updates to the WHO Antifungal Pipeline
3
FDA Tentatively Approves First Generic Lenacapavir PrEP for 120 LMICs
4
Postapproval Surveillance Confirms Ceftobiprole Activity Against MRSA
5